Evidence map›Paper›PMID 36931644›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2023

K

Alexis Doucette, Kayla Johnson, Shelby Hulke, Sunna Mujteba, Elena Miller, Belle Meyer, Peter I Dosa, Amanda H Klein

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Fixing a Broken Heart Opens the Door to Developing KThe Journal of pharmacology and experimental therapeutics · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alexis DoucetteDepartment of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, Minnesota (A.D., K.J., S.H., S.M., E.M., B.M., A.H.K.) and Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota (P.I.D.).
Kayla JohnsonDepartment of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, Minnesota (A.D., K.J., S.H., S.M., E.M., B.M., A.H.K.) and Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota (P.I.D.).
Shelby HulkeDepartment of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, Minnesota (A.D., K.J., S.H., S.M., E.M., B.M., A.H.K.) and Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota (P.I.D.).
Sunna MujtebaDepartment of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, Minnesota (A.D., K.J., S.H., S.M., E.M., B.M., A.H.K.) and Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota (P.I.D.).
Elena MillerDepartment of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, Minnesota (A.D., K.J., S.H., S.M., E.M., B.M., A.H.K.) and Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota (P.I.D.).
Belle MeyerDepartment of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, Minnesota (A.D., K.J., S.H., S.M., E.M., B.M., A.H.K.) and Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota (P.I.D.).
Peter I DosaDepartment of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, Minnesota (A.D., K.J., S.H., S.M., E.M., B.M., A.H.K.) and Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota (P.I.D.).
Amanda H KleinDepartment of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, Minnesota (A.D., K.J., S.H., S.M., E.M., B.M., A.H.K.) and Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota (P.I.D.) ahklein@d.umn.edu.ORCID 0000-0002-3433-2180
University of Minnesota, Duluth · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
KATP Channels as Downstream targets of adenylyl cyclases during opioid tolerance and withdrawalR01DA051876 · NIDA · UNIVERSITY OF MINNESOTA · PI KLEIN, AMANDA HELEN · 2021 to 2025
$2.9M
Altering potassium channel activity to investigate morphine tolerance and opiate induced hypersensitivityK01DA042902 · NIDA · UNIVERSITY OF MINNESOTA · PI KLEIN, AMANDA HELEN · 2018 to 2022
$726k
NCATS NIH HHS UL1 TR002494NIDA NIH HHS K01 DA042902NIDA NIH HHS R01 DA051876
6 · The paper itself

Abstract

Previous studies show ATP-sensitive potassium (K

Indexed as

Chronic PainHypersensitivityNeuralgiaProdrugsAdenosine TriphosphateAnalgesics, OpioidAnimalsDrug ToleranceFemaleMaleMiceMorphineAdenosine TriphosphateAnalgesics, OpioidMorphineProdrugs

Identifiers

PMID36931644
PMCPMC10519579
OpenAlexW4327713637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.